Skip to main content
Chongqing Pharscin Pharmaceutical Co., Ltd. logo

Chongqing Pharscin Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002907 ISIN · CNE100003308 LEI · 300300M2F5XMGFAYMA24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,115 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002907

About Chongqing Pharscin Pharmaceutical Co., Ltd.

https://www.pharscin.com

Chongqing Pharscin Pharmaceutical Co., Ltd. is an integrated enterprise specializing in the research, development, production, and commercialization of chemical drugs and modern traditional Chinese medicine. The company focuses on therapeutic areas such as digestive system health, cardiovascular and cerebrovascular diseases, and hepatobiliary conditions. Its portfolio includes a variety of proprietary formulations and generic medications, notably treatments for chronic liver disease and gastrointestinal disorders. Pharscin maintains advanced manufacturing facilities and a dedicated R&D infrastructure focused on enhancing drug efficacy and delivery systems. The organization emphasizes clinical value and technological innovation to provide comprehensive healthcare solutions across diverse medical sectors.

Recent filings

Filing Released Lang Actions
关于公司收到化学原料药再注册批准通知书的公告
Regulatory Filings Classification · 87% confidence The document is a regulatory announcement by a listed company (Chongqing Hausen Pharmaceuticals) disclosing receipt of a drug re-registration approval notice from the local drug regulatory authority. It does not present financial results, board changes, dividends, or an actual report, but rather a compliance announcement under listing rules. It fits the “Regulatory Filings” category (RNS).
2026-05-19 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an official announcement of the 2025 Annual Shareholders’ Meeting resolutions, including detailed voting results for each agenda item. It does not present full financial statements or serve as an investor presentation; rather, it reports the outcomes of shareholder votes. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-15 Chinese
上海泽昌律师事务所关于重庆华森制药股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 75% confidence The document is a legal opinion letter (法律意见书) issued by Shanghai Zechang Law Firm regarding the 2025 Annual General Meeting of Chongqing Huasen Pharmaceutical Co., Ltd. It details the convening procedures, attendee qualifications, agenda items, voting procedures, and voting results, and provides the firm’s legal conclusions. It is not the AGM materials themselves (presentations or slide decks), nor a standalone proxy statement or declaration of voting results in the narrow sense, nor a financial report. It is a compliance/legal opinion document that does not fit a more specific category, so it falls under the generic Regulatory Filings (RNS) fallback category.
2026-05-15 Chinese
关于公司产品完成境内生产药品备案的公告
Regulatory Filings Classification · 90% confidence The document is an announcement by Chongqing Huasen Pharmaceutical regarding the completion of a domestic drug production filing (extension of the product’s shelf life) with the National Medical Products Administration. It contains operational/regulatory details rather than financial statements, management changes, or shareholder information. It does not qualify as any specialized financial report category and is best classified under the fallback “Regulatory Filings (RNS)” for miscellaneous compliance disclosures.
2026-05-12 Chinese
关于公司独立董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director from the company's board. It details the resignation circumstances, legal compliance, and the impact on board composition. There is no financial data, no report attached or referenced as being published, and no mention of financial results or regulatory certifications. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2026-05-08 Chinese
审计委员会关于会计师事务所2025年度履职评价及履行监督职责情况的报告
Audit Report / Information Classification · 75% confidence The document is a detailed report from the company’s Audit Committee on its evaluation and supervision of the external auditor’s performance for the 2025 audit. It is not an Annual Report, earnings release, or management discussion, but rather a standalone audit‐related information report covering auditor qualifications, procedures, oversight activities, and overall supervision results. This aligns with the ‘Audit Report / Information (AR)’ category, which covers standalone audit reports and related audit information (excluding full annual reports).
2026-04-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.